Initial Management of Pustular Psoriasis

Introduction to Pustular Psoriasis Management

The American Academy of Dermatology recommends hospital admission for patients presenting with generalized pustular or erythrodermic psoriasis due to risk of systemic involvement and potential mortality 3, 4
The British Association of Dermatologists suggests that infliximab demonstrates superior efficacy with rapid and often complete disease clearance, making it the preferred first-line biologic therapy at standard dosing of 5 mg/kg infused at weeks 0, 2, and 6, then every 8 weeks thereafter 1

The National Institute for Health and Care Excellence recommends acitretin (25-50 mg daily) as the preferred conventional systemic agent for pustular psoriasis, with response times as early as 3 weeks 2, 3
The American College of Rheumatology suggests that cyclosporine (2.5-5 mg/kg daily) achieves response in approximately 3 weeks but requires careful monitoring of blood pressure and renal function 2
The European Academy of Dermatology and Venereology recommends that methotrexate (15-25 mg weekly) is less preferred for pustular variants but may be considered with appropriate monitoring of liver function and complete blood counts 2

The American Academy of Dermatology advises to never prescribe systemic corticosteroids for pustular psoriasis—they precipitate severe disease exacerbation, erythrodermic psoriasis, or generalized pustular flares upon discontinuation, potentially causing fatal deterioration 1, 2, 5

The British Association of Dermatologists recommends starting with moderately potent topical corticosteroids (British National Formulary grade III) to relieve symptoms 3
The National Institute for Health and Care Excellence suggests that topical coal tar and dithranol may provide some benefit when corticosteroids are insufficient 3
The European Academy of Dermatology and Venereology recommends that systemic acitretin can be considered for refractory localized disease 3
The American College of Dermatology suggests that ustekinumab (IL-12/23 inhibitor at 90 mg) shows 67% clearance rates in palmoplantar pustular psoriasis for moderate-to-severe cases 5

The American Academy of Dermatology recommends obtaining complete blood count, lipid panel, and liver function tests before initiating acitretin, with ongoing monitoring of lipids and hepatic function 2
The British Association of Dermatologists suggests that baseline serum creatinine and blood pressure should be obtained before initiating cyclosporine, with regular monitoring of both parameters due to glomerulosclerosis and hypertension risk 2
The National Institute for Health and Care Excellence recommends obtaining complete blood count, liver function tests, and serum creatinine at baseline before initiating methotrexate, with regular hepatic monitoring 2
The European Academy of Dermatology and Venereology advises to screen for active or latent tuberculosis, hepatitis B, and fungal infections before initiating biologics (infliximab) due to increased infection risk 1

The American College of Obstetricians and Gynecologists recommends that all commonly used systemic agents are absolutely contraindicated in pregnancy 3, 4
The British Association of Dermatologists suggests that before prescribing to women of childbearing age, explicitly explain teratogenic risks and document that the patient understands the absolute necessity for reliable contraception 3, 4